paclitaxel / Generic mfg. - LARVOL DELTA

ABIGAIL: ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL (clinicaltrials.gov) - P2 | N=162 | Completed | Sponsor: MedSIR | Active, not recruiting ➔ Completed

Trial completion • Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

Overcoming Multidrug Resistance in Cancer Cells Targeting ABC Transporter ABCB1 with Tyrosine Kinase Inhibitor: Olverembatinib. (PubMed, Exp Cell Res) - "Non-cytotoxic concentrations of olverembatinib significantly increased the sensitivity of ABCB1-overexpressing cells to paclitaxel and vincristine. Additionally, olverembatinib activated the ATPase activity of ABCB1 in a concentration-dependent manner and exhibited potent binding affinity to ABCB1 in docking simulations. These findings suggest that olverembatinib holds promise as a potent reversal agent for MDR, paving the way for its integration into novel combination chemotherapy regimens to improve cancer treatment outcomes."

Journal • Oncology • ABCB1

Rupestonic acid targets ENO1 to exert antitumor activity and synergizes with paclitaxel in hepatocellular carcinoma. (PubMed, Toxicol Appl Pharmacol) - "These findings suggest that rupestonic acid is a promising candidate for HCC treatment. They also underscore the potential of rupestonic acid in the design and development of lead compounds for HCC treatment and identify ENO1 as a viable therapeutic target."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • ENO1

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery (clinicaltrials.gov) - P2 | N=20 | Completed | Sponsor: University of Nebraska | Active, not recruiting ➔ Completed | Trial completion date: Nov 2026 ➔ Dec 2025

Trial completion • Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Neutropenia • Oncology • Solid Tumor • HER-2

A diagnostic pitfall: Therapy-related acute promyelocytic leukemia mimicking mixed-phenotype acute leukemia (ASH 2025) - "The BC was treated according to national guidelines with surgery, radiation therapy, chemotherapy (4 cycles of etoposide and cyclophosphamide and 12 cycles of paclitaxel), and endocrine maintenance therapy and has been in remission ever since...Induction therapy was immediately initiated according to the current APL treatment standard with tretinoin (ATRA) and arsenic trioxide (ATO) plus a single dose of idarubicin based on the APOLLO study for cytoreduction because the patient developed hyperleukocytosis mainly due to administration of corticosteroids...(II.) Even in the context of previous chemotherapy, genetic testing is mandatory as t-APL is treated specifically and shows a better prognosis than other forms of therapy-related AML. (III.) It highlights the importance of careful integrated diagnostics for acute leukemias that incorporate morphology, flow cytometry, and genetic results to guide therapeutic decision-making."

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Breast Cancer • Gene Therapies • Hematological Malignancies • Leukemia • Solid Tumor

FDG-PET-based Selective De-escalation of Chemoradiation in Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma: a Multi-center Phase II Trial. (PubMed, Clin Cancer Res) - "FDG-PET-based RT dose personalization resulted in promising LRR outcomes in early stage oropharynx cancer with improved short- term PROs. Furthermore, HPVctDNA changes early in treatment may predict LRC."

Journal • P2 data • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial. (PubMed, Clin Cancer Res) - "This phase II trial of neoadjuvant nivolumab plus carboplatin and paclitaxel in previously untreated, locally-advanced, resectable SCCHN was well tolerated and reached its primary endpoint of pCR at the primary site. A phase III confirmatory study is warranted in advanced-stage, resectable HPV-negative SCCHN."

Journal • P2 data • Head and Neck Cancer • Oncology • Oral Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Trilaciclib for the prevention of chemotherapy-induced myelosuppression: A systematic review and meta-analysis (ASH 2025) - "Chemotherapy regimens were heterogeneous and included etoposide-platinum (E/P) (either cisplatin or carboplatin) (n=5), gemcitabine/carboplatin (GCb) (n=2), topotecan (n=2), FOLFOXIRI (n=1), and Carboplatin/Paclitaxel/Tislelizumab (n=1)...It also showed a positive impact on progression-free and overall survival, without compromising chemotherapy effectiveness or increasing toxicity. These findings highlight Trilaciclib's potential as a valuable adjunct to chemotherapy in appropriately selected patients."

Retrospective data • Review • Breast Cancer • Colorectal Cancer • Febrile Neutropenia • Infectious Disease • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia • Triple Negative Breast Cancer

Inhibition of DOCK1 prevents the clonal expansion of high-risk TP53-mutant clonal hematopoiesis induced by genotoxic stressors. (ASH 2025) - "Our TP53-mutant human CH models faithfully recapitulates the clonal expansion ofTP53-mutant CH upon exposure to genotoxic stressors, including olaparib and paclitaxel. Further, weidentify DOCK1 as a potential SL partner with mutant TP53 demonstrating that inhibition of DOCK1 canprevent clonal expansion of TP53mut CH."

Hematological Malignancies • DOCK1 • TP53

Research Progress of Docetaxel Nano-Drug Delivery System in the Treatment of Breast Cancer. (PubMed, Int J Nanomedicine) - "Docetaxel (DTX), a chemotherapeutic agent derived from paclitaxel (PTX), has received approval from the US Food and Drug Administration (FDA) for the treatment of BC and various other malignancies...Furthermore, key challenges limiting clinical translation are analysed. This paper provides a theoretical foundation and practical guidance for rationally designing DTX nanomedicines, accelerating their transition from laboratory research to clinical application and offering new hope for BC treatment."

Journal • Review • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER

Development of a senescence-related lncRNA signature in endometrial cancer based on multiple machine learning models. (PubMed, Front Genet) - "Paclitaxel, gemcitabine, and cisplatin (all p < 0.05) may be more useful in EC patients with high expression of targeted srlncRNAs in the GDSC database. The EC-18 PDO was more resistant to three drugs, which aligned with clinical observation. The srlncRNA signature (AL121906.2, AP002761.4, BX322234.1, LINC00662, LINC00908, VIM-AS1, and ZNF236-DT) could guide prognosis prediction and treatment choices for EC patients."

IO biomarker • Journal • Endometrial Cancer • Oncology • Solid Tumor • VIM-AS1 • ZKSCAN1 • ZNF23

Tumor inhibition in xenograft model of diffuse intrinsic pontine glioma via ultra-low and low-frequency magnetic field therapy. (PubMed, Electromagn Biol Med) - "Mouse survival models of DIPG, subsequently exposed to the rfe_A1A signal, demonstrated significantly longer survival times and biomarker changes in Ki67 expression, consistent with a slowdown in cell-division rates. The rfe_A1A signal significantly increased survival time in a DIPG model, a novel strategy tested in clinical studies and compassionate use cases."

Journal • Preclinical • Brain Cancer • Diffuse Intrinsic Pontine Glioma • Diffuse Midline Glioma • Glioma • Oncology • Solid Tumor

CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy. (PubMed, bioRxiv) - "Here, we investigated the efficacy of first-in-class CB2-specific antibody agonists (AB110 and AB120) and an isotype control (AB100) on mechanical and cold hypersensitivity induced by paclitaxel in both tumor-free and mammary (4T1) tumor-bearing female mice. The cytotoxic activity of paclitaxel on 4T1 tumor cell line was maintained in the presence of CB2 antibody agonists in vitro . Overall, our results suggest that CB2-specific antibody agonists are promising candidates for treating CIPN, providing lasting pain relief without tolerance, off target effects or unwanted CB1-mediated motor side effects."

Journal • Breast Cancer • Immunology • Oncology • Pain • Peripheral Neuropathic Pain

S-1 maintenance chemotherapy following definitive chemoradiotherapy in high-risk locally advanced nasopharyngeal carcinoma: a propensity score-matched analysis. (PubMed, Front Immunol) - "All patients received two to three cycles of TPF (paclitaxel liposome, cisplatin, and fluorouracil) neoadjuvant chemotherapy, followed by concurrent chemoradiotherapy within 1-2 weeks later...Patients with non-keratinizing carcinoma or EBV DNA positivity showed a trend toward improved DMFS as well.Safety:S-1 maintenance chemotherapy demonstrated a favorable safety profile, with only 3.2% of patients experiencing grade 3 adverse events. S-1 maintenance chemotherapy after definitive chemoradiotherapy significantly improves DMFS and OS in patients with high-risk locally advanced NPC, with a favorable safety profile."

Journal • Retrospective data • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma (clinicaltrials.gov) - P3 | N=130 | Not yet recruiting | Sponsor: AIDS Malignancy Consortium | Trial completion date: Dec 2029 ➔ Nov 2027 | Trial primary completion date: Mar 2028 ➔ Dec 2026

Head-to-Head • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Kaposi Sarcoma • Oncology • Sarcoma • Solid Tumor

Invited Discussant – Asian perspectives on DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC) (ESMO Asia 2025) - No abstract available

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC) (ESMO Asia 2025) - No abstract available

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer: The CAPItello-290 phase III trial extended China cohort (ESMO Asia 2025) - P3 | "OS and PFS numerically favoured C + P over pbo + P in pts with PIK3CA/AKT1/PTEN-altered tumours, but interpretation is limited by small sample size and wide confidence intervals. No new safety concerns with C + P were identified."

Clinical • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PIK3CA • PTEN

Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESMO Asia 2025) - P3 | "Here, we report the final outcomes and explore the potential genomic biomarkers predictive of long-term survival of JUPITER-06 trial. A total of 514 previously untreated patients with advanced or metastatic ESCC were randomly assigned in a 1:1 ratio to receive either toripalimab or placebo, in combination with paclitaxel and cisplatin. Final analysis of the JUPITER-06 trial confirms the sustained OS benefit of toripalimab plus chemotherapy as first-line treatment in advanced/metastatic ESCC, with a manageable safety profile. ccTMB and the extended EGIC scheme show promising predictive value for long-term survival in anti-PD-1-based combination therapies."

Biomarker • IO biomarker • Metastases • P3 data • Tumor mutational burden • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • PD-L1 • TMB

A prospective, multi-center phase II study: Evaluating the efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy in laryngeal/hypopharyngeal squamous cell carcinoma (L/HPSCC) (ESMO Asia 2025) - P2 | "Pts received 3 cycles of pembrolizumab combined with paclitaxel and cisplatin, followed by surgery + RT/CRT (pts who refuse or unable to undergo surgery received definitive RT/CRT). Future studies will extend to the second-stage to explore the efficacy of subsequent treatment options."

Clinical • P2 data • Hypopharyngeal Cancer • Oncology • Squamous Cell Carcinoma

A 66-Year-Old Woman with EGFR-Mutant Lung Adenocarcinoma and Brain Metastases Achieving 96-Month Overall Survival with serially deploying three distinct third-generation EGFR-TKIs (ESMO Asia 2025) - "First-line icotinib plus paclitaxel/nedaplatin was given and achieved PR and 36-month PFS...Osimertinib 80mg qd combined with pemetrexed chemotherapy for 5 cycles, followed by osimertinib monotherapy, yielded 25-month PFS until isolated CNS progression. Despite concomitant whole-brain radiotherapy and bevacizumab with Osimertinib, intracranial lesions advanced...This exceptional survival in advanced EGFR+ NSCLC was achieved through initial chemo-TKI therapy, sequential third-generation TKIs (osi→almo→furmo) for CNS control, and furmonertinib dose escalation for late CNS progression. The persistent TP53 co-mutation suggests a resistance mechanism, while PD-L1 negativity excluded immunotherapy, demonstrating the efficacy of optimized TKI sequencing alone."

Clinical • IO biomarker • Brain Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1 • TP53

Immune checkpoint inhibitor–related meningitis: two cases with contrasting clinical course and outcome (ESMO Asia 2025) - "Case 1: A 69-year-old man with stage T4N3M1 small-cell lung cancer achieved a near-complete response after EP + Durvalumab ×4, followed by 7 cycles of maintenance...Case 2: A 41-year-old woman with stage cT4bN2M0 triple-negative breast cancer received neoadjuvant Paclitaxel/Carboplatin + Pembrolizumab ×4, then AC + Pembrolizumab ×4, followed by mastectomy...These cases underscore the wide spectrum of ICI-related meningitis—from atypical autoimmune antibody–positive presentation with full recovery to fulminant leptomeningeal involvement and rapid fatality. Early recognition, exclusion of infection, and tailored immunosuppression are crucial for prognosis."

Checkpoint inhibition • Clinical • Breast Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer

A new era in metastatic endometrial carcinoma: Integrating chemotherapy, immunotherapy, targeted therapy and antibody-drug conjugates (ESMO Asia 2025) - "This case illustrates an evolving treatment landscape, including the use of immunotherapy and trastuzumab deruxtecan (Tdxd) in the HER2 2+ setting...She received first line therapy with paclitaxel and carboplatin...She presented with disease progression in feb 2023, for which she received 2nd line pembrolizumab and lenvatinib till oct 2023... This case highlights the shifting treatment paradigm in advanced endometrial carcinoma, demonstrating how the sequential use of chemotherapy, immunotherapy, targeted therapy, and radiotherapy can extend disease control and improve survival. It highlights the potential role of Tdxd in HER2-low metastatic endometrial carcinoma, even in heavily pretreated patients. Careful toxicity monitoring is essential to optimize outcomes."

Metastases • Endometrial Cancer • Oncology • Solid Tumor • CCNE1 • ER • HER-2 • TP53

Thyroid metastasis from cervical cancer: A rare case report and literature review (ESMO Asia 2025) - "The patient received six cycles of paclitaxel and carboplatin as systemic therapy. This case emphasizes the importance of considering metastatic disease in the differential diagnosis of new thyroid lesions in patients with prior malignancies. Accurate diagnosis through histopathological and immunohistochemical correlation is essential to guide optimal management and avoid unnecessary or ineffective treatments."

Case report • Clinical • Review • Cervical Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Thyroid Gland Carcinoma • KRT5 • NKX2-1 • TP63

Triple-negative breast cancer with somatic BRCA1 mutation and metaplastic progression in a young woman: A case report (ESMO Asia 2025) - "She underwent modified radical mastectomy with sentinel lymph node biopsy, followed by adjuvant doxorubicin–cyclophosphamide (AC) for 4 cycles, which was complicated by pneumonitis and heart failure. Weekly paclitaxel for 11 cycles was discontinued due to fatigue and elevated troponin, despite a normal ECG...She received gemcitabine–cisplatin for 2 cycles with stable disease, followed by cytoreductive palliative surgery with reconstruction, and then 2 additional cycles of gemcitabine–cisplatin...She was treated with docetaxel–capecitabine for 1 cycle with poor response, followed by sacituzumab govitecan for 3 cycles, which resulted in disease progression. Currently, the patient is on eribulin plus durvalumab, having completed 1 cycle...This case illustrates an unusual histological evolution from medullary carcinoma to metaplastic carcinoma, and subsequently to mucoepidermoid carcinoma. It raises important questions about the optimal timing of genomic testing and the..."

Case report • Clinical • IO biomarker • Tumor mutational burden • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Salivary Gland Cancer • Solid Tumor • Squamous Cell Carcinoma • Triple Negative Breast Cancer • BRCA • BRCA1 • HER-2 • PD-L1 • PGR • PTEN • RB1 • SF3B1 • STK11 • TMB • TP53